{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T21:18:34Z","timestamp":1694121514808},"reference-count":21,"publisher":"Japan Society for Clinical Immunology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2177\/jsci.39.478","type":"journal-article","created":{"date-parts":[[2016,10,29]],"date-time":"2016-10-29T18:08:28Z","timestamp":1477764508000},"page":"478-484","source":"Crossref","is-referenced-by-count":11,"title":["TAFRO syndrome with primary Sjogren's syndrome"],"prefix":"10.2177","volume":"39","author":[{"given":"Nozomi","family":"IWANAGA","sequence":"first","affiliation":[{"name":"Departments of General Internal Medicine and Rheumatology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"HARADA","sequence":"additional","affiliation":[{"name":"Departments of General Internal Medicine and Rheumatology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshika","family":"TSUJI","sequence":"additional","affiliation":[{"name":"Departments of General Internal Medicine and Rheumatology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieko","family":"KAWAHARA","sequence":"additional","affiliation":[{"name":"Departments of General Internal Medicine and Rheumatology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"KUROHAMA","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumori","family":"IZUMI","sequence":"additional","affiliation":[{"name":"Departments of General Internal Medicine and Rheumatology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"YOSHIDA","sequence":"additional","affiliation":[{"name":"Departments of Hematology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"FUJIKAWA","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Isahaya Genaral Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"ITO","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"KAWAKAMI","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nagasaki University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"MIGITA","sequence":"additional","affiliation":[{"name":"Departments of General Internal Medicine and Rheumatology, Nagasaki Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) \u9ad8\u4e95\u548c\u6c5f\uff0c\u4ed6\uff1a\u767a\u71b1\uff0c\u80f8\u6c34\uff0c\u809d\u813e\u816b\u3092\u4f34\u3044\uff0c\u9aa8\u9ac4\u306b\u8efd\u5ea6\u306e\u7dda\u7dad\u5316\u3092\u8a8d\u3081\u308b\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\uff0e\u81e8\u5e8a\u8840\u6db2<b>51<\/b>: 320-325, 2010."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kojima, M., et al.: Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. <i>Int J Surg Pathol<\/i>. <b>16<\/b>: 391-398, 2008.","DOI":"10.1177\/1066896908315812"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kawabata, H., et al.: Clinical features and treatment of multicentric castleman&apos;s disease: a retrospective study of 21 Japanese patients at a single institute. <i>J Clin Exp Hematop<\/i>. <b>53<\/b>: 69-77, 2013.","DOI":"10.3960\/jslrt.53.69"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kawabata, H., et al.: Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). <i>J Clin Exp Hematop<\/i>. <b>53<\/b>: 57-61, 2013.","DOI":"10.3960\/jslrt.53.57"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) \u68ee\u3000\u8302\u90ce\uff0c\u4ed6\uff1a\u8457\u3057\u3044\u591a\u30af\u30ed\u30fc\u30f3\u6027\u9ad8\u514d\u75ab\u30b0\u30ed\u30d6\u30ea\u30f3\u8840\u75c7\u3068\u5168\u8eab\u30ea\u30f3\u30d1\u7bc0\u306e\u9ad8\u5ea6\u306e\u5f62\u8cea\u7d30\u80de\u5897\u751f\u3092\u5448\u3059\u308b\u75c7\u5019\u7fa4\uff0e\u5f62\u8cea\u7d30\u80de\u578bCastleman\u30ea\u30f3\u30d1\u816b\u3068\u306e\u7570\u540c\uff0e\u65e5\u7db2\u5185\u8a8c<b>20<\/b>: 85-94, 1980.","DOI":"10.3960\/jslrt1961.20.Supplement_85"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Fajgenbaum, D.C., et al.: HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. <i>Blood<\/i>. <b>123<\/b>: 2924-2933, 2014.","DOI":"10.1182\/blood-2013-12-545087"},{"key":"7","unstructured":"7) Muskardin, T.W., et al.: Castleman disease and associated autoimmune disease. <i>Curr Opin Rheumatol<\/i>. <b>24<\/b>: 76-83, 2012."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Kojima, M., et al.: Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother. <b>60<\/b>: 663-672, 2006.","DOI":"10.1016\/j.biopha.2006.09.004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Muskardin, T.W., et al.: Castleman disease and associated autoimmune disease. <i>Curr Opin Rheumatol<\/i>. <b>24<\/b>: 76-83, 2012.","DOI":"10.1097\/BOR.0b013e32834db525"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kojima, M., et al.: Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. <i>Pathol Res Pract<\/i>. <b>203<\/b>: 423-431, 2007.","DOI":"10.1016\/j.prp.2007.03.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kiss, E., et al.: Myelofibrosis in systemic lupus erythematosus. <i>Leuk Lymphoma<\/i>. <b>39<\/b>: 661-665, 2000.","DOI":"10.3109\/10428190009113399"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Paquette, R.L., et al.: Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. <i>Medicine (Baltimore)<\/i>. <b>73<\/b>: 145-152, 1994.","DOI":"10.1097\/00005792-199405000-00003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Masaki, Y., et al.: Japanese variant of multicentric castleman&apos;s disease associated with serositis and thrombocytopenia\u2013a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? <i>J Clin Exp Hematop<\/i>. <b>53<\/b>: 79-85, 2013.","DOI":"10.3960\/jslrt.53.79"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Keller, A.R., et al.: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. <i>Cancer<\/i>. <b>29<\/b>: 670-683, 1972.","DOI":"10.1002\/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Takai, K., et al.: Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases. <i>J Clin Exp Hematop<\/i>. <b>53<\/b>: 63-68, 2013.","DOI":"10.3960\/jslrt.53.63"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Inoue, M., et al.: Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. <i>J Clin Exp Hematop<\/i>. <b>53<\/b>: 95-99, 2013.","DOI":"10.3960\/jslrt.53.95"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kawabata, H., et al.: Successful treatment of a patient with multicentric Castleman&apos;s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. <i>Intern Med<\/i>. <b>52<\/b>: 1503-1507, 2013.","DOI":"10.2169\/internalmedicine.52.9482"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kubokawa, I., et al.: The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman&apos;s disease. <i>BMC Pediatr<\/i>. <b>14<\/b>: 139, 2014.","DOI":"10.1186\/1471-2431-14-139"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Awano, N., et al.: A case of multicentric castleman&apos;s disease of mixed-type, which showed constellation of symptoms, i.e., thrombocytopenia, anasarca, anemia, fever, myelofibrosis, and lymphadenopathy. <i>J Clin Exp Hematop<\/i>. <b>53<\/b>: 101-105, 2013.","DOI":"10.3960\/jslrt.53.101"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Iwaki, N., et al.: Atypical hyaline vascular-type castleman&apos;s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. <i>J Clin Exp Hematop<\/i>. <b>53<\/b>: 87-93, 2013.","DOI":"10.3960\/jslrt.53.87"},{"key":"21","unstructured":"21) \u5c0f\u6fa4\u5b5d\u5e78\uff0c\u4ed6\uff1aRotuximab\u304c\u8457\u52b9\u3057\u305fTAFRO\u75c7\u5019\u7fa4\u3068\u601d\u308f\u308c\u308bCastleman\u75c5\u985e\u4f3c\u75c7\u4f8b\uff0e\u81e8\u5e8a\u8840\u6db2<b>55<\/b>: 350-355, 2014."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["TAFRO\u75c7\u5019\u7fa4\u985e\u4f3c\u306e\u81e8\u5e8a\u50cf\u3092\u5448\u3057\u305f\u539f\u767a\u6027\u30b7\u30a7\u30fc\u30b0\u30ec\u30f3\u75c7\u5019\u7fa4\u306e1\u4f8b"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/39\/5\/39_478\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T00:38:26Z","timestamp":1568507906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/39\/5\/39_478\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.39.478","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}